References
- Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653
- Dietz AB, Souan L, Knutson GJ, et al. Imatinib inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–1049
- Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339
- Mattiuzzi G, Cortes JE, Talpaz M, et al. Development of varicella-zoster virus infection in patients with chronic myeloid leukemia treated with imatinib mesylate. Clin Cancer Res 2003; 9: 976–980
- Bekkenk MW, Vermeer MH, Meijer JLM, et al. EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood 2003; 102: 4243
- Lin JT, Lee MY, Hsiao LT, et al. Pulmonary nocardiosis in a patient with CML relapse undergoing imatinib therapy after bone marrow transplantation. Ann Hematol 2004; 83: 444–446
- Kullberg BJ, Oude Lashof AML. Epidemiology of opportunistic invasive mucoses. Eur J Med Res 2002; 7: 183–191
- Boktour MR, Kontoyiannis DP, Hanna HA, et al. Multiple-species candidemia in patients with cancer. Cancer 2004; 101: 1860–1865
- Petrocheilou-Paschou V, Georgilis K, Kontoyannis D, et al. Pneumonia due to Candida krusei. Clin Microbiol Infect 2002; 8: 806–809
- Lorenz E, Frees KL, Schwartz DA. Determination of the TLR4 genotype using allele-specific PCR. Biol Blood Marrow Transplant 2001; 31: 22–24
- Ogus AC, Yoldas B, Ozdemir T, et al. The Arg753Gln polymorphism of the human Toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004; 23: 219–223
- Lokeshwar N, Kumar L, Kumari M. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myeloid leukemia. Leuk Lymphoma 2005; 46: 781–784
- Gambillara E, Laffitte E, Widmer N, et al. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology 2005; 211: 363–365
- Selleslag D. A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta Biomed 2006; 77(Suppl. 2)32–35
- Netea MG, Van der Graaf C, Van der Meer JWM, Kullberg BJ. Recognition of fungal pathogens by Toll-like receptors. Eur J Clin Microbiol Infect Dis 2004; 23: 672–676
- Roeder A, Kirschning CJ, Rupec RA, et al. Toll-like receptors as key mediators in innate antifungal immunity. Med Mycol 2004; 42: 485–498
- Van der Graaf CA, Netea MG, Morre SA, et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006; 17: 29–34